<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>596</ReferenceId>
        <DateLastUpdated>2020-10-11-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15618169</PubmedId>
            <Abstract>Increasing antibiotic resistance and a rising patient population at risk for infection due to impaired immunity underscore the importance of vaccination against pneumococci. However, available capsular polysaccharide vaccines are often poorly immunogenic in patients at risk for pneumococcal disease. The goal of this study was to explore the potential of peptide mimotopes to function as alternative vaccine antigens to elicit a type-specific antibody response to pneumococci. We used a human monoclonal immunoglobulin A (IgA) antibody (NAD) to type 8 Streptococcus pneumoniae capsular polysaccharide (type 8 PS) to screen a phage display library, and the phage PUB1 displaying the peptide FHLPYNHNWFAL was selected after three rounds of biopanning. Inhibition studies with phage-displayed peptide or the peptide PUB1 and type 8 PS showed that PUB1 is a mimetic of type 8 PS. PUB1 conjugated to tetanus toxoid (PUB1-TT) induced a type 8 PS-specific antibody response in BALB/c mice, further defining it as a mimotope of type 8 PS. The administration of immune sera obtained from PUB1-TT-immunized mice earlier (days 14 and 21) and later (days 87 and 100) after primary and reimmunization resulted in a highly significant prolongation of the survival of naive mice after pneumococcal challenge compared to controls. The survival of PUB1-TT-immunized mice was also prolonged after pneumococcal challenge nearly 4 months after primary immunization. The efficacy of PUB1-TT-induced immune sera provides proof of principle that a mimotope-induced antibody response can protect against pneumococci and suggests that peptide mimotopes selected by type-specific human antibodies could hold promise as immunogens for pneumococci.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>325-33</ArticlePages>
            <ArticleTitle>A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Buchwald</LastName>
                    <ForeName>Ulrike K</ForeName>
                </Author>
                <Author>
                    <LastName>Lees</LastName>
                    <ForeName>Andrew</ForeName>
                </Author>
                <Author>
                    <LastName>Steinitz</LastName>
                    <ForeName>Michael</ForeName>
                </Author>
                <Author>
                    <LastName>Pirofski</LastName>
                    <ForeName>Liise-Anne</ForeName>
                </Author>
            </Authors>
            <Affiliations>Albert Einstein College of Medicine, Division of Infectious Diseases, Room 709 Forchheimer Bldg., 1300 Morris Park Ave., Bronx, NY 10461, USA.</Affiliations>
            <ArticleChemicalList>Antibodies, Bacterial;CPG-oligonucleotide;Oligodeoxyribonucleotides;Pneumococcal Vaccines;Polysaccharides, Bacterial;Tetanus Toxoid;Vaccines, Conjugate;pneumococcal polysaccharide, type 8;NAD</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Bacterial(blood; immunology); Cross Reactions; Female; Immunization; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; NAD(metabolism); Oligodeoxyribonucleotides(pharmacology); Pneumococcal Vaccines(immunology); Polysaccharides, Bacterial(immunology); Tetanus Toxoid(immunology); Vaccines, Conjugate(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>73</Volume>
                <Issue>1</Issue>
                <Title>Infection and immunity</Title>
                <Issn>0019-9567</Issn>
                <MedlineTa>Infect Immun</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>S. pneumoniae type 8 PS mimotope</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>FHLPYNHNWFAL</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <EpitopeRelatedObject>
                    <RelatedObjectType>The epitope is a mimotope of:</RelatedObjectType>
                    <RelatedObject>
                        <AccessionNonSequenceMolecule>
                            <ChemicalType>Carbohydrate</ChemicalType>
                            <Molecule>
                                <ChEBIId>CHEBI:18154</ChEBIId>
                            </Molecule>
                            <SourceOrganismId>10001801</SourceOrganismId>
                        </AccessionNonSequenceMolecule>
                    </RelatedObject>
                </EpitopeRelatedObject>
                <LocationOfData>Materials and methods</LocationOfData>
                <EpitopeId>16123</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 3 and text page P328</LocationOfData>
                        <BCellId>1853772</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>FHLPYNHNWFAL</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>PUB1-TT</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA23282.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>1513</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>CpG</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 10 µg, administered on days 0, 14 and 35.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with PUB1 with an N-terminal cysteine residue conjugated to dextran and tetanus toxoid with or without adjuvants CpG and aluminum hydroxide gel.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>311</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope inhibited serum IgG from PUB1-TT immunized mice from binding to solid-bound PUB1. The epitope (PUB1) did not cross inhibit PUB1-TT immunized mice serum binding to type 8 PS.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>PUB1</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>FHLPYNHNWFAL</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ObjectLibrary>
                                    <DisplaySystemType>Phage display</DisplaySystemType>
                                </ObjectLibrary>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 3 and text page 328</LocationOfData>
                        <BCellId>1853773</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>FHLPYNHNWFAL</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>PUB1-TT</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA23282.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>1513</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>CpG</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 10 µg, administered on days 0, 14 and 35.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with PUB1 with an N-terminal cysteine residue conjugated to dextran and tetanus toxoid with or without adjuvants CpG and aluminum hydroxide gel.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>311</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Soluble type 8 PS (type 8 Streptococcus pneumoniae capsular polysaccharide) inhibited PUB1-TT immunized mouse serum from binding to solid-phase type 8 PS, but did not cross inhibited serum binding to the epitope PUB1.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Carbohydrate</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:18154</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>10001801</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <BCellId>1853786</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>FHLPYNHNWFAL</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>PUB1-TT</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ObjectLibrary>
                                        <DisplaySystemType>Phage display</DisplaySystemType>
                                    </ObjectLibrary>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>CpG</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 10 µg, administered on days 0, 14 and 35.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with PUB1 with an N-terminal cysteine residue conjugated to dextran and tetanus toxoid with or without adjuvants CpG and aluminum hydroxide gel.</ImmunizationComments>
                        </Immunization>
                        <AdoptiveTransfer>
                            <RecipientOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 weeks</Age>
                            </RecipientOrganism>
                            <TransferredAntibodyMolecule>
                                <TransferredAntibodyMoleculeSourceMaterial>Serum</TransferredAntibodyMoleculeSourceMaterial>
                                <TransferredAntibodyMoleculeImmunoglobulinDomain>Entire Antibody</TransferredAntibodyMoleculeImmunoglobulinDomain>
                                <TransferredAntibodyMoleculePurificationStatus>Polyclonal</TransferredAntibodyMoleculePurificationStatus>
                            </TransferredAntibodyMolecule>
                            <AdoptiveTransferComments>Mus musculus C57BL/6 were adoptively transferred with Serum.</AdoptiveTransferComments>
                        </AdoptiveTransfer>
                        <AssayInformation>
                            <AssayTypeId>598</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Adoptive transfer of sera from PUB1-TT- or PUB1-TT/CpG/Al-immunized BALB/c mice protected recipient C57BL/6 mice from infecting with type 8 pneumococci with 80 to 100% survival. Passive transfer of PUB1-TT-induced immune sera obtained on days 14 and 21 after primary immunization protected 90%, and sera obtained on days 87 and 100 after primary immunization protected 100% of mice.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Streptococcus pneumoniae type 8</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10001801</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Results text page 327</LocationOfData>
                        <BCellId>1853815</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:874</DiseaseState>
                                <DiseaseStage>Unknown</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Other</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>1313</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The details of NAD (human monoclonal IgA1) information were described in the cited reference: Steinitz, M. et al. 1986. Eur. J. Immunol. 16: 187-193. [PMID: 3007166].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>311</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Phage PUB1 (the epitope contained in the phage) inhibited 62% of NAD binding to solid bound type 8 PS (type 8 Streptococcus pneumoniae), and the phage PUB1 directly bound NAD by immunopanning.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>NAD</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgA1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>FHLPYNHNWFAL</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ObjectLibrary>
                                    <DisplaySystemType>Phage display</DisplaySystemType>
                                </ObjectLibrary>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>11885</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>FHLPYNHNWFAL</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>PUB1-TT</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA23282.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>1513</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>CpG</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 10 µg, administered on days 0, 14 and 35.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with PUB1 with an N-terminal cysteine residue conjugated to dextran and tetanus toxoid with or without adjuvants CpG and aluminum hydroxide gel.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>PUB1-specific IgM in PUB1-TT immunized mice peaked on day 28, with titers of 1:1,300 in the PUB1-TT group and 1:3,300 in the PUB1-TT/CpG-Al group. The preimmune serum had IgM to PUB1.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>PUB1</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>FHLPYNHNWFAL</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ObjectLibrary>
                                    <DisplaySystemType>Phage display</DisplaySystemType>
                                </ObjectLibrary>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>11883</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>FHLPYNHNWFAL</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>PUB1-TT</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA23282.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>1513</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>CpG</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 10 µg, administered on days 0, 14 and 35.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with PUB1 with an N-terminal cysteine residue conjugated to dextran and tetanus toxoid with or without adjuvants CpG and aluminum hydroxide gel.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Preimmune serum from PUB1 conjugate-immunized mice reacted with type 8 PS at titers of 1:540 for IgM. On day 7, type 8 PS-specific IgM in the PUB1-TT and PUB1-TT/CpG-Al groups increased 5.5- to 6.5-fold compared to preimmune serum values. Type 8 PS-specific IgM peaked on day 14, with titers of 1:7,000 in the PUB1-TT group and 1:8,000 in the PUB1-TT/CpG-Al group and decreased thereafter. A slight boost response was observed on day 49, 14 days after the second boost.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Carbohydrate</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:18154</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>10001801</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 4 and 5</LocationOfData>
                        <BCellId>11889</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>FHLPYNHNWFAL</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>PUB1-TT</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA23282.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>1513</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>CpG</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 10 µg, administered on days 0, 14 and 35.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with PUB1 with an N-terminal cysteine residue conjugated to dextran and tetanus toxoid with or without adjuvants CpG and aluminum hydroxide gel.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>125</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Administration of PUB1-TT or PUB1-TT/CpG-Al protected mice from infection with Streptococcus pneumoniae type 8 as shown by estimating the lengths of mice survival and bacterial burden in blood of the immunized mice.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Streptococcus pneumoniae type 8</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10001801</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 1, 2 and 3</LocationOfData>
                        <BCellId>1853714</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>FHLPYNHNWFAL</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>PUB1-TT</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA23282.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>1513</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>CpG</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 10 µg, administered on days 0, 14 and 35.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with PUB1 with an N-terminal cysteine residue conjugated to dextran and tetanus toxoid with or without adjuvants CpG and aluminum hydroxide gel.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Type 8 PS-specific IgG in the PUB1 conjugate-immunized mice appeared between days 7 and 14. The response of the group that received the adjuvants was more rapid than that of the one that did not. The PUB1-TT/CpG-Al group showed a titer of 1:2,600 on day 14 and a peak titer of 1:3,000 at day 28. The PUB1-TT group not receiving adjuvants had a slower increase of type 8 PS-specific IgG, with a peak titer of 1/2,200 on day 49. Following day 49, the titers decreased in both groups but remained 6- to 11-fold above baseline values. IgG3 dominated the early type 8 PS-specific response, but IgG1 titers increased over time. In the PUB1-TT group, type 8 PS-specific IgG2a titers were below the lowest tested serum dilution (1:150) at most times. CpG-Al was associated with higher proportions of type 8 PS-specific IgG2a and IgG3.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Carbohydrate</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:18154</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>10001801</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 1, 2 and 3</LocationOfData>
                        <BCellId>1853716</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>FHLPYNHNWFAL</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>PUB1-TT</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA23282.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>1513</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>CpG</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 10 µg, administered on days 0, 14 and 35.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with PUB1 with an N-terminal cysteine residue conjugated to dextran and tetanus toxoid with or without adjuvants CpG and aluminum hydroxide gel.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>PUB1-specific IgG in PUB1-TT immunized mice peaked on day 49, with titers of 1:1,50000 in the PUB1-TT group and 1:700,000 in the PUB1-TT/CpG-Al group on day 28. The preimmune serum had no IgG to PUB1. IgG1 and IgG2a were the predominant subclasses of PUB1-specific antibodies at all times. CpG-Al was associated with higher proportions of PUB1-specific IgG1 and IgG2a.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>PUB1</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>FHLPYNHNWFAL</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ObjectLibrary>
                                    <DisplaySystemType>Phage display</DisplaySystemType>
                                </ObjectLibrary>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

